Jiangsu Hengrui Pharmaceuticals (01276): SHR-6914 Injection receives drug clinical trial approval notice.
Jiangsu Hengrui Medicine (01276) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for SHR-6914 injection. The company will start clinical trials in the near future.
Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration (NMPA) for the SHR-6914 injection, and will soon begin clinical trials.
SHR-6914 injection is an innovative anti-tumor drug independently developed by the company, intended for the treatment of prostate cancer. As of now, there are no similar drugs approved for sale domestically or internationally. As of now, the cumulative research and development investment for the SHR-6914 injection project is approximately 29.2 million yuan (unaudited).
Related Articles
EVERG VEHICLE (00708) receives additional resumption guidance from the Stock Exchange and will continue to be suspended.
China Rare Earth Resources And Technology (00769): Zhang Chengcai Appointed as Independent Non-Executive Director
On June 16th, DUALITYBIO-B (09606) spent HK$9.7749 million to repurchase 53,900 shares.
EVERG VEHICLE (00708) receives additional resumption guidance from the Stock Exchange and will continue to be suspended.
China Rare Earth Resources And Technology (00769): Zhang Chengcai Appointed as Independent Non-Executive Director
On June 16th, DUALITYBIO-B (09606) spent HK$9.7749 million to repurchase 53,900 shares.
RECOMMEND
